

Biostar Pharmaceuticals, Inc.  
Form 8-K  
August 18, 2009

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2009

BIOSTAR PHARMACEUTICALS, INC.  
(Exact name of registrant as specified in its charter)

|   |  |  |
|---|--|--|
| Maryland<br>(State or other jurisdiction<br>of incorporation) | 333-147363<br>(Commission File Number) | 20-5101287<br>(IRS Employer<br>Identification No.) |
|---|--|--|

|   |                      |
|---|----------------------|
| No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's<br>Republic of China<br>(Address of principal executive offices) | 712046<br>(Zip Code) |
|---|----------------------|

Registrant's telephone number, including area code: 86-029-33686638

Copies to:  
Benjamin Tan, Esq.  
Sichenzia Ross Friedman Ference LLP  
61 Broadway, 32 Floor  
New York, New York 10006  
Phone: (212) 930-9700  
Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
-

Edgar Filing: Biostar Pharmaceuticals, Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act  
(17 CFR 240.14d-2(b))

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act  
(17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition

On August 14, 2009, Biostar Pharmaceuticals, Inc., a Maryland corporation (the “Company”), announced its results of operations for the six months ended June 30, 2009. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

Item 8.01 Other Events

On August 12, 2009, the Company issued a press release annexed hereto as Exhibit 99.2 hereto.

The information in this report, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference in any registration statement or other document filed under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filings, except as shall be expressly set forth by specific reference in such a filing.

Item Financial Statements and Exhibits

9.01

(d) Exhibits

99.1 Press Release, dated August 14, 2009, issued by Biostar Pharmaceuticals, Inc.

99.2 Press Release, dated August 12, 2009, issued by Biostar Pharmaceuticals, Inc

---

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOSTAR PHARMACEUTICALS, INC.

Dated: August 18, 2009

By: /s/ Ronghua Wang  
Name: Ronghua Wang  
Title: Chief Executive Officer

